PLEASE NOTE

Microsoft has ended support for its pre-IE11 browsers as of January 2016 and will be discontinuing IE11 support in August 2021.

If you are seeing this message, you are viewing the site on one of these unsupported browsers. We only support the recent versions of major browsers such as Chrome, Firefox, Safari, and Edge.

Thank you.

(click to close and continue using this browser)

Sign InDues Join Donate Privacy Contact Search
Home News Scrip

Scrip

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below.

John Lezcano
Corporate Account Manager
M: (631) 807-4971
John.lezcano@informa.com

Pharma intelligence | informa
P: (212) 652-2678
pharmaintelligence.informa.com

Scrip
Tuesday, March 19, 2024
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others...
Monday, March 18, 2024
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about...
Monday, March 18, 2024
The British drug maker’s move follows that of Boehringer Ingelheim earlier this month, which itself followed increasing political scrutiny on...
Monday, March 18, 2024
Norgine will market Pedmark, indicated to reduce risk of chemotherapy-related hearing loss in pediatric cancer, in the EU and UK...
Monday, March 18, 2024
Private Company Edition: After US-based Alumis and Sionna raised $259m and $182m, respectively, in series C rounds, Tubulis in Munich...
Monday, March 18, 2024
The group is pushing sonelokimab into pivotal trials in two indications and starting from scratch in three more. What comes...
Monday, March 18, 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies...
Monday, March 18, 2024
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such...
Monday, March 18, 2024
Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s...
Sunday, March 17, 2024
BeiGene's first US approval for Tevimbra (tislelizumab), based on an Asia-heavy global study, is expected to pave the way for...